• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Supernus Pharmaceuticals (SUPN) Is Back In The Spotlight, But Why?

    Simply Wall St·10/27/2026 21:13:11
    语音播报

    Supernus Pharmaceuticals (SUPN) has terminated its UBS revolving credit line as it prepares to close a merger with Indivior Pharmaceuticals. The move clears existing collateral ties and anticipates a new senior secured facility.

    Supernus Pharmaceuticals trades at US$40.77 after a recent 7 day share price return of 2.33%. However, the 90 day share price return is down 14.58% and the 1 year total shareholder return has declined 22.67%, while the 3 year total shareholder return is up 72.61%. This suggests that longer term holders have still seen meaningful gains despite recent pressure around merger related headlines.

    Seize this merger moment around Supernus Pharmaceuticals to uncover other potential breakout candidates with resilient balance sheets using our curated list of solid balance sheet and fundamentals (24 results).

    Bulls point to Supernus Pharmaceuticals’ CNS portfolio and merger-driven scale, while bears focus on recent share price weakness and current losses. Which side does the present valuation actually support as the deal and new credit facility approach?

    Most Popular Narrative: 34% Undervalued

    On Simply Wall St’s most followed view, Supernus Pharmaceuticals screens as undervalued, with a fair value of $61.75 against a last close of $40.77. That gap rests on the idea that the Indivior tie up turns today’s CNS portfolio into a much larger revenue and earnings platform over time.

    Significant balance sheet resources and a focus on transactions remain in play, now exemplified by the proposed all stock merger of equals with Indivior that would combine approximately $2.2b of pro forma net revenue, $888m of pro forma adjusted EBITDA and expected annual cost synergies of $125m. This can lift overall earnings power and margins for the combined CNS portfolio.

    See why 8 investors see Supernus Pharmaceuticals as 34% undervalued.

    Result: Fair Value of $61.75 (UNDERVALUED)

    Still, the Supernus Pharmaceuticals story can change quickly if Indivior integration stumbles or if the company struggles to lift revenue from its broader CNS portfolio.

    Find out about the key risks to this Supernus Pharmaceuticals narrative.

    Next Steps

    If the sentiment in this piece feels mixed, that is by design, and it is your cue to move quickly and stress test the numbers yourself. To see what is driving optimism around Supernus Pharmaceuticals, review its 3 key rewards.

    Looking for more Supernus Pharmaceuticals sized ideas?

    Do not stop your research with Supernus Pharmaceuticals. Use focused screeners to surface fresh candidates that fit your risk tolerance, income needs, and value goals.